Disclosure Statement for Refractory HSV Management in Immunocompromised Patients

This article appears to be a brief clinical resource or CME-related piece addressing the management of refractory herpes simplex virus (HSV) in immunocompromised patients. It is presented by Dr. Roy F. Chemaly from MD Anderson Cancer Center, who discloses numerous financial relationships with pharmaceutical companies. The content is extremely short (133 words) and consists almost entirely of a disclosure statement, with no substantive clinical guidance, evidence, or treatment recommendations actually provided in the text.

Supported by an independent educational grant from AiCuris.12d ago1 min readen

health

Read on mdsc.pe

Key quotes

Roy F. Chemaly, MD, MPH, has disclosed the following relevant financial relationships: Served as an advisor or consultant for: ADMA Biologics; AiCuris; Ansun Pharmaceuticals; AssemblyBio; AstraZeneca; Biotest; Eurofins-Viracor; IntegerBio; Invivyd; Merck/MSD; Moderna; Pfizer; Revvity; Shionogi; Symbio; Takeda

Served as a speaker or a member of a speakers bureau for: Merck/MSD

From the article

Refractory HSV in immunocompromised patients demands more than standard care. Get the latest evidence to recognize, escalate, and treat with confidence.

Continue reading on mdsc.pe

You might also wanna read

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of VG2025 Intravenous Injection in Subjects With Advanced Solid Tumors

clinicaltrials.gov·3d ago

CMV-CMI in csCMVi After HSCT

clinicaltrials.gov·2d ago

Molecular Microbiology- Guided Antimicrobial Stewardship Versus Standard Stewardship in Hospitalized Patients

clinicaltrials.gov·3d ago

CAR-T in Relapsed/Refractory Multiple Myeloma

clinicaltrials.gov·1d ago

Evaluation of Safety and Efficacy of Virus Specific T-Cell Administration in Pediatric Patients With Systemic Viral Infection Following Allogeneic Hematopoietic Stem Cell Transplantation.